These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 24451380)

  • 1. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
    Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
    Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oleanolic acid induces a dual agonist action on PPARγ/α and GLUT4 translocation: A pentacyclic triterpene for dyslipidemia and type 2 diabetes.
    Loza-Rodríguez H; Estrada-Soto S; Alarcón-Aguilar FJ; Huang F; Aquino-Jarquín G; Fortis-Barrera Á; Giacoman-Martínez A; Almanza-Pérez JC
    Eur J Pharmacol; 2020 Sep; 883():173252. PubMed ID: 32534078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
    Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
    Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.
    Kim SH; Hong SH; Park YJ; Sung JH; Suh W; Lee KW; Jung K; Lim C; Kim JH; Kim H; Park KS; Park SG
    Sci Rep; 2019 Feb; 9(1):1656. PubMed ID: 30733541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
    Jeong HW; Lee JW; Kim WS; Choe SS; Kim KH; Park HS; Shin HJ; Lee GY; Shin D; Lee H; Lee JH; Choi EB; Lee HK; Chung H; Park SB; Park KS; Kim HS; Ro S; Kim JB
    Diabetes; 2011 Feb; 60(2):496-506. PubMed ID: 21270261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
    Ito Y; Yamamoto M; Furukawa S; Fukui M; Morishita K; Kitao T; Shirahase H
    Biol Pharm Bull; 2021; 44(5):659-668. PubMed ID: 33952822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice.
    Bak EJ; Kim J; Choi YH; Kim JH; Lee DE; Woo GH; Cha JH; Yoo YJ
    Clin Nutr; 2014 Feb; 33(1):156-63. PubMed ID: 23623334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
    J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
    Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
    Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
    Ming Y; Hu X; Song Y; Liu Z; Li J; Gao R; Zhang Y; Mei H; Guo T; Xiao L; Wang B; Wu C; Xiao X
    PLoS One; 2014; 9(7):e102102. PubMed ID: 25004107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
    Jung HY; Kim B; Ryu HG; Ji Y; Park S; Choi SH; Lee D; Lee IK; Kim M; Lee YJ; Song W; Lee YH; Choi HJ; Hyun CK; Holzapfel WH; Kim KT
    Diabetes Obes Metab; 2018 Jul; 20(7):1688-1701. PubMed ID: 29516607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
    Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
    Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice.
    Huan Y; Pan X; Peng J; Jia C; Sun S; Bai G; Wang X; Zhou T; Li R; Liu S; Li C; Liu Q; Liu Z; Shen Z
    Diabetes Obes Metab; 2019 Nov; 21(11):2553-2563. PubMed ID: 31364797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.